Zheng-Yi Zhou

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 4

Top Topics

Rheumatoid Arthritis

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

PharmacoEconomics - open

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal of medical economics

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Zheng-Yi Zhou, Mark E Bensink, Nisha C Hazra, Chunyi Xu, Bruce M Hendry, Claire C Sharpe, Mo Zhou
Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis. PharmacoEconomics - open (2024)
Georgina V Long, Evan J Lipson, F Stephen Hodi, Paolo Antonio Ascierto, James M G Larkin, Christopher Lao, Jean-Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk, Viviana Garcia-Horton, Zheng-Yi Zhou, Yiqiao Xin, Jennell Palaia, Laura McDonald, Sarah Keidel, Anthony Salvatore, Divya Patel, Leon A Sakkal, Hussein A Tawbi, Dirk Schadendorf
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Beilei Cai, Zheng-Yi Zhou, Weiguang Xue, Nisha C Hazra, Mukesh Singh, Dinesh Mishra, Diana Brixner, Gary Oderda, Joseph Biskupiak
Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States. Journal of medical economics 24 (1) (2021)
Zheng-Yi Zhou, Jenny Griffith, Ella Xiaoyan Du, Daniel Chin, Keith A Betts, Arijit Ganguli
Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis. Advances in therapy 33 (5) (2016)